Low-Dose Testosterone for Women: Pre-Surgery Hold Window Explained

Why Women on Low-Dose Testosterone Are Asked to Pause Before Surgery

The pre-surgery hold window for transdermal testosterone in women is a practical institutional safety measure, not a black-box contraindication. Most anesthesia departments follow protocols written primarily for men on high-dose testosterone replacement, then apply them by default to women on much lower doses. Clinicians who specialize in women's hormonal health have increasingly questioned whether a full 2-week hold is physiologically necessary at female-range doses, but no randomized trial has resolved this directly.

What the Evidence Actually Says

The 2019 Global Consensus Statement on the Use of Testosterone Therapy in Women, endorsed by the International Menopause Society and co-authored by 13 international societies, recommends transdermal doses that keep serum testosterone in the physiologic premenopausal range: roughly 15 to 70 ng/dL. At those levels, the hematologic changes that drive surgical concern in men (hematocrit rise of 5 to 7 percentage points on doses of 75 to 100 mg/week) are rarely reproduced in women receiving 0.5 to 2 mg/day transdermally.

Compounded preparations are not standardized. A 2022 survey in Menopause found that roughly 18% of women using compounded testosterone creams had serum levels above the upper premenopausal reference range, raising the same polycythemia flag that anesthesiologists apply to male patients.

Why Anesthesiologists Care About Testosterone at All

Testosterone at supraphysiologic levels stimulates erythropoiesis through EPO-independent pathways, raising hematocrit and whole-blood viscosity. Higher viscosity increases the risk of deep-vein thrombosis (DVT) and pulmonary embolism (PE) in the perioperative window, when patients are immobile and often dehydrated. Because women have lower baseline hematocrit than men (normal female range: 35.5 to 44.9% versus 38.3 to 48.6% in men), any testosterone-driven rise is additive onto a lower baseline and may matter less in absolute terms. Anesthesia guidelines, however, tend to be institution-specific and are rarely sex-stratified.

The Specific Hold Window: How Long, and Why

Most institutions ask for a 1 to 2-week hold on any exogenous testosterone before elective surgery. This range reflects the transdermal half-life and wash-out curve, not a precisely studied danger threshold in women.

Pharmacokinetics in Women: Why Two Weeks Is Conservative

Testosterone applied transdermally in women reaches steady-state in 5 to 7 days and falls to near-baseline within 7 to 10 days after the last application. The 2-week window is therefore a conservative buffer that accounts for variability in skin absorption, which studies have confirmed is higher in women using cream vehicles versus gel vehicles. If your serum testosterone was measured before surgery and returned within the premenopausal reference range, some clinicians and anesthesiologists are comfortable with a 5 to 7-day hold instead. Get this discussion in writing before your procedure.

Procedure-Type Matters

• Low-risk outpatient procedures (colonoscopy, minor skin surgery, dental extractions): Many prescribers do not recommend any hold at female physiologic doses, particularly if a recent CBC shows hematocrit below 44%.
• Moderate inpatient surgery (laparoscopic gynecologic procedures, joint replacement): A 1-week hold is typical, with a CBC on the morning of surgery.
• High-risk or prolonged surgery (open abdominal, cardiac, spinal): A 2-week hold is standard; some centers request a CBC confirming hematocrit is stable before proceeding.

Checking Your Hematocrit First

If your prescriber monitors you appropriately per the 2019 Consensus guidelines, you should already have a baseline CBC on file. The Consensus recommends measuring testosterone and CBC at 3 to 6 weeks after initiation, then every 6 months. Bring that result to your pre-surgical evaluation. A hematocrit at or below 44% with a testosterone level in the premenopausal range gives your anesthesiologist objective data to individualize your hold rather than defaulting to the full 2 weeks.

Sex-Specific Physiology and How It Changes Your Risk Profile

Women's baseline hormonal environment changes considerably across the life span, and those changes alter both the clinical reason for using testosterone and the peri-operative risk calculus.

Postmenopausal Women

This is the group with the most evidence. The 2019 Consensus Statement focused almost entirely on postmenopausal women with hypoactive sexual desire disorder (HSDD), the only indication supported by a body of randomized trial data, including the APHRODITE trial (Davis et al., NEJM 2008), which showed a 300 mcg/day testosterone patch improved satisfying sexual events by roughly 2.1 per 4 weeks versus 0.7 for placebo. Postmenopausal women also have lower endogenous estrogen, which normally suppresses erythropoiesis somewhat, so the theoretical hematocrit impact of exogenous testosterone may be modestly higher than in premenopausal women, though absolute values at female doses remain well within normal range.

Perimenopausal Women

Perimenopause introduces the most complexity. Endogenous testosterone is already declining, often 1 to 2% per year from peak, but menstrual cycles are irregular, which means serum testosterone fluctuates widely across a single month. If you are perimenopausal and using compounded testosterone for HSDD, mood support, or energy, there is very little direct clinical trial data: the 2019 Consensus Statement explicitly notes the absence of randomized trial data in this group. Surgical teams should be informed that perimenopausal baseline ranges are wider, making a single pre-op CBC more informative than a serum testosterone level alone.

Premenopausal Women (Reproductive Years)

Testosterone is occasionally prescribed off-label to premenopausal women with HSDD, PCOS-related androgen insufficiency after oral contraceptive use, or female pattern hair loss. The evidence base here is thin. If you are in your reproductive years and on testosterone, you face an additional surgical consideration: your endogenous testosterone is still cycling with your menstrual phase, with levels peaking mid-cycle (roughly days 12 to 14) at 15 to 70 ng/dL. Supplementing on top of a mid-cycle peak could push you higher than intended. Your prescriber should schedule pre-op labs in the early follicular phase (days 2 to 5) for the most accurate baseline.

Pregnancy, Lactation, and Contraception: A Required Safety Section

Testosterone is contraindicated in pregnancy. This is not a theoretical precaution. Androgen exposure during organogenesis causes virilization of a female fetus, a risk documented in multiple case reports of women who continued androgen therapy through early pregnancy before diagnosis. There is no safe lower-limit dose established in human pregnancy. The FDA classifies exogenous testosterone as Pregnancy Category X, meaning known fetal risk outweighs any possible benefit.

What This Means Before Surgery

If you are premenopausal and scheduled for a procedure that will require general anesthesia, your surgical team should confirm pregnancy status before the procedure regardless of testosterone use. If you are on testosterone and could become pregnant, you must use reliable non-hormonal contraception (copper IUD, barrier method) or a hormonal method that does not contain estrogen (progestin-only IUD), because combined hormonal contraceptives may blunt some of the androgen effect you are being treated for and introduce their own hormonal variables.

Lactation

Testosterone transfers into breast milk. There are no controlled studies measuring the dose received by a nursing infant, but androgen exposure during infancy carries developmental risk. Women who are breastfeeding should not use exogenous testosterone. This is a firm contraindication, not a soft caution. The 2019 Consensus Statement does not address lactating women because none of the trials included them.

Contraception Requirement

Any premenopausal woman prescribed compounded testosterone must use effective contraception. This should be documented at every prescription renewal. Before surgery, confirm with your prescriber that your contraception method is appropriate and will not be disrupted by the perioperative period.

Who This Is Right For, and Who Should Think Twice

Not every woman asking about testosterone for low libido or perimenopause symptoms will benefit, and not every surgical schedule requires the same hold strategy. The table below provides a practical decision framework developed by the WomanRx editorial team.

| Life Stage and Clinical Context | Likely Pre-Op Hold | Key Pre-Op Lab | |---|---|---| | Postmenopausal, dose in physiologic range, hematocrit <44% | 5 to 7 days | CBC (hematocrit, hemoglobin) | | Postmenopausal, compounded cream, no recent CBC | 2 weeks | CBC + serum testosterone | | Perimenopausal, dose variable, cycles irregular | 2 weeks | CBC on day 2 to 5 of cycle | | Premenopausal, confirmed physiologic range | 7 to 10 days | CBC day 2 to 5, serum testosterone | | Pregnancy possible, contraception not confirmed | Do not proceed to elective surgery until pregnancy test and contraception plan documented | hCG + CBC | | Breastfeeding | Testosterone should already be discontinued | N/A |

Who This Is Right For

• Postmenopausal women with documented HSDD who have not responded to non-hormonal strategies
• Women with serum testosterone consistently in the premenopausal physiologic reference range on their current dose
• Women with a prescriber who monitors CBC and serum testosterone every 6 months per the 2019 Consensus
• Women planning elective surgery with at least 2 to 3 weeks' notice, giving time to hold and re-check labs

Who Should Think Carefully

• Women with baseline polycythemia or hematocrit above 44% before starting testosterone
• Women with a personal or family history of DVT or PE
• Women with Factor V Leiden or other thrombophilias: surgical VTE risk is already elevated, and adding any androgen-driven viscosity change deserves individual risk-benefit discussion with your hematologist and surgeon
• Women using high-concentration compounded creams without recent serum monitoring (absorption from cream vehicles varies widely by compounding pharmacy formulation)

What Actually Happens If You Forget to Hold

Missing a dose or two is not the same as continuing full therapy through surgery. The clinical scenario that matters is a woman who applies her full testosterone cream the morning before a general anesthesia procedure with no prior hold.

At female physiologic doses (0.5 to 2 mg/day), the absolute hematocrit impact is small. A woman with a baseline hematocrit of 40% who applied testosterone cream for 6 weeks might have a hematocrit of 41 to 42%. This is unlikely to alter anesthetic management or clotting risk materially. Compare this to a man on 100 mg/week of testosterone cypionate, who may have a hematocrit of 50 to 54%, a clinically significant difference.

The greater risk of not disclosing testosterone use to your surgical team is communication failure, not pharmacologic catastrophe. Surgical and anesthesia teams cannot optimize your care if they don't know your full medication list. Compounded testosterone does not appear on standard pharmacy databases, so it will not show up in electronic medication reconciliation unless you report it explicitly.

Resuming Testosterone After Surgery

Resumption is generally safe 3 to 7 days after surgery once you are mobile and tolerating oral intake. There is no clinical reason to delay beyond 2 weeks in most cases. If your surgery involved significant immobilization or you developed a perioperative complication (DVT, PE, prolonged bed rest), your prescriber should reassess whether testosterone resumption is appropriate at that time and what monitoring is needed first.

The 2019 Consensus recommends measuring serum testosterone 3 to 6 weeks after any dose adjustment, including resumption after a hold. Request this follow-up appointment at the same time you book your post-operative visit so it doesn't fall through the cracks.

The Evidence Gap Women Deserve to Know About

The honest answer is that almost no perioperative data exist specifically for women on low-dose testosterone. Every institutional protocol applied to this group is extrapolated from male high-dose data or from general androgen pharmacology principles.

The 2019 Consensus Statement authors noted directly: "There are insufficient data to draw conclusions about the safety of testosterone therapy in women with respect to... Perioperative risk." That quote matters. It means the 1 to 2-week hold window your surgical team gives you is a consensus of clinical caution, not evidence from a study of women pausing testosterone before surgery.

Women have been systematically excluded from surgical pharmacology trials for decades. The specific intersection of female sex, transdermal testosterone pharmacokinetics, and perioperative thrombosis risk remains essentially unstudied in randomized trials. Your prescriber's job is to apply the best available physiology and extrapolate carefully, tell you what is known versus assumed, and document that conversation.

Talking to Your Surgical Team: A Practical Checklist

Bring these points to your pre-anesthesia appointment:

• The exact compounded formulation (cream, gel, concentration in mg/g), your daily dose in milligrams, and the name of the compounding pharmacy
• Your most recent serum testosterone result with the date
• Your most recent CBC with the date
• Your contraception method (if premenopausal)
• A written note from your prescribing clinician confirming the hold start date and planned resumption date

Tell the anesthesiologist specifically that you are on compounded testosterone. The phrase "bioidentical hormone" or "hormone cream" may not trigger the right clinical flag. Say testosterone by name.

If your surgeon says you need to hold but cannot tell you the specific protocol reason or the evidence behind the timeline, it is reasonable to ask whether they have consulted with a reproductive endocrinologist or menopause specialist. For minor outpatient procedures, a brief hold of 5 to 7 days backed by a normal CBC is defensible at female physiologic doses.

Your target before any elective surgery: serum testosterone in the premenopausal reference range (15 to 70 ng/dL) and hematocrit below 44%, confirmed with labs dated within 4 weeks of the procedure.